Skip to main content
main-content

24-10-2018 | Head and neck cancer | Video

KEYNOTE-048: Phase III study of first-line pembrolizumab for recurrent/metastatic head and neck squamous cell carcinoma

Barbara Burtness talks through the results of the KEYNOTE-048 trial comparing pembrolizumab alone or with chemotherapy versus the EXTREME regimen for patients with recurrent or metastatic head and neck cancer (5:10).

Funding for this video was provided in part by F. Hoffmann-La Roche Ltd, Basel, Switzerland.

See the research in context now

with trial summaries, expert opinion and congress coverage

Image Credits